国际眼科纵览 ›› 2014, Vol. 38 ›› Issue (5): 346-351.doi: 10.3760/ cma. j. issn.1673-5803.2014.05.012

• 综述 • 上一篇    下一篇

诱导多能干细胞在视网膜疾病治疗中的应用研究

孙建国  李丹  余晓波  吴继红  孙兴怀   

  1. 1. 200031上海,复旦大学附属眼耳鼻喉科医院眼科;2. 200433复旦大学聚合物分子工程国家重点实验室
  • 收稿日期:2014-04-11 出版日期:2014-10-22 发布日期:2014-10-24
  • 通讯作者: 孙兴怀,Email:xhsun@shmu.edu.cn
  • 基金资助:

    复旦大学聚合物分子工程国家重点实验室开放研究课题(K2013-16)

Application of induced pluripotent stem cells in treating retinal diseases

SUN Jian-guo1,2, LI Dan1, YU Xiao-bo1, WU Ji-hong1, SUN Xing-huai1   

  1. 1 EENT Hospital, Shanghai Medical College, Fudan University,  Shanghai 200031, China; 2 State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200433, China
  • Received:2014-04-11 Online:2014-10-22 Published:2014-10-24
  • Contact: SUN Xing-huai, Email: xhsun@shmu.edu.cn

摘要: 近年来诱导多能干细胞(induced pluripotent stem cells, iPSC)作为一种有用的干细胞来源在基础研究和临床实验方面得到广泛应用。基于iPSC的视网膜细胞替换技术在治疗某些视网膜和视神经疾病方面取得进展,主要包括视网膜色素上皮、感光细胞和视网膜神经节细胞等。基于iPSC的细胞替换技术通过多种不同技术方法实现iPSC向视网膜细胞诱导分化,进而将获得的目标细胞移植到视网膜受损动物模型,取得了一定的治疗效果。然而,在iPSC技术从实验室走向临床应用的道路上还有大量问题需要解决。(国际眼科纵览, 2014, 38: 346-351)

Abstract: Induced pluripotent stem cells(iPSC) have made a remarkable influence on science, technology and medicine by providing an available source of human cells for basic research and clinical applications. The aim of this article was to review the recent research progresses of iPSC in treating ocular diseases, especially in the treaments of retina and optic nerve diseases. Here we mainly reviewed the current literatures on the cell replacement therapy of retina and optic nerve diseases based on iPSC induction and differentiation technology, including retinal pigment epithelium, photoreceptor and retinal ganglion cells. The security and the existing problems of iPSC technology have also been discussed. Plenty of significant advancements have been made using different methods and protocols to differentiate iPSC into target retinal cells and transplant cells into animal model with untreatable retinal diseases. However, many challenges remained in the road from iPSC research to clinical application.  (Int Rev Ophthalmol, 2014, 38:  346-351)